Gilead Sciences reports almost $900 mn in Q3 remdesivir sales

Gilead reported a jump in third-quarter sales in part due to nearly $900 million in revenues from Remdesivir, a treatment for Co
Gilead reported a jump in third-quarter sales in part due to nearly $900 million in revenues from Remdesivir, a treatment for Covid-19

Remdesivir, a therapeutic to treat Covid-19, boosted third-quarter sales for pharmaceutical company Gilead Sciences by nearly $900 million, according to results released Wednesday by the drugmaker.

The medication, sold under the brand name Veklury and originally developed to treat Ebola, has been shown to shorten the for patients hospitalized with the new coronavirus.

Gilead reported a 17 percent jump in third-quarter revenues to $6.6 billion.

The company reported a profit of $360 million, compared with a loss of $1.2 billion in the year-ago period.

The US Food and Drug Administration last Thursday granted full approval to the antiviral drug as a treatment for patients hospitalized with Covid-19, after conditional authorization was given in May.

Remdesivir, which is administered by an injection, was one of the first drugs to show relative promise in treating the virus, although its efficacy in reducing its mortality rate is unproven.

President Donald Trump, who tested positive for the coronavirus early in October, was treated with remdesivir—among other drugs—at a military hospital outside Washington.

Shares of Gilead fell 1.4 percent to 57.90 in after-hours trading.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2020 AFP

Citation: Gilead Sciences reports almost $900 mn in Q3 remdesivir sales (2020, October 29) retrieved 24 November 2020 from https://medicalxpress.com/news/2020-10-gilead-sciences-mn-q3-remdesivir.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments